Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment

By MarketWatch   |   1 year ago
Corbus Pharmaceuticals Receives Fast Track from FDA for Cervical Cancer Treatment

Corbus Pharmaceuticals' treatment for metastatic cervical cancer, CRB-701, has received fast-track designation from the FDA. The drug targets Nectin-4 overexpression in cancers, with first trial data expected in 2025.

Read More

Did you find this insightful?